BACKGROUND: Despite growing utilization of accelerated partial breast irradiation using brachytherapy (APBI-Brachy) for elderly breast cancer patients, there are limited data from randomized Phase III trials to support its routine use. This study uses population-based data to examine whether APBI-Brachy results in comparable survival rates compared with whole breast irradiation (WBI). METHODS: A sample of 29,647 female patients diagnosed with nonmetastatic breast cancer in 2002-2007 treated with breast-conserving surgery and radiotherapy was identified in the Surveillance, Epidemiology, and End Results Program-Medicare data set. Log-rank tests, Cox proportional hazards models, instrumental variable analysis, and subgroup analysis were used to study the comparative effectiveness of APBI-Brachy and WBI. RESULTS: During a median followup of 3.6 and 4.8 years, 123 (7.7%) and 3438 (13.6%) patients died after APBI-Brachy and WBI, respectively. Recurrence-free survival (p = 0.9711) and overall survival rates (p = 0.0551) did not differ significantly between the two radiation modalities. After accounting for tumor characteristics, patient characteristics, community factors, and comorbidities, the recurrence-free survival (hazard ratio, 1.05; 95% confidence interval, 0.90-1.23; p = 0.5125) and overall survival (hazard ratio, 0.87; 95% confidence interval, 0.72-1.04; p = 0.1332) rates were still not significantly different between patients treated with APBI-Brachy and WBI. CONCLUSION: Partial breast brachytherapy and WBI resulted in similar recurrence-free and overall survival rates in this cohort of elderly breast cancer patients, even after adjustment for the more favorable characteristics of patients in the former group. These findings will need to be confirmed by the randomized trials comparing these modalities.
BACKGROUND: Despite growing utilization of accelerated partial breast irradiation using brachytherapy (APBI-Brachy) for elderly breast cancerpatients, there are limited data from randomized Phase III trials to support its routine use. This study uses population-based data to examine whether APBI-Brachy results in comparable survival rates compared with whole breast irradiation (WBI). METHODS: A sample of 29,647 female patients diagnosed with nonmetastatic breast cancer in 2002-2007 treated with breast-conserving surgery and radiotherapy was identified in the Surveillance, Epidemiology, and End Results Program-Medicare data set. Log-rank tests, Cox proportional hazards models, instrumental variable analysis, and subgroup analysis were used to study the comparative effectiveness of APBI-Brachy and WBI. RESULTS: During a median followup of 3.6 and 4.8 years, 123 (7.7%) and 3438 (13.6%) patients died after APBI-Brachy and WBI, respectively. Recurrence-free survival (p = 0.9711) and overall survival rates (p = 0.0551) did not differ significantly between the two radiation modalities. After accounting for tumor characteristics, patient characteristics, community factors, and comorbidities, the recurrence-free survival (hazard ratio, 1.05; 95% confidence interval, 0.90-1.23; p = 0.5125) and overall survival (hazard ratio, 0.87; 95% confidence interval, 0.72-1.04; p = 0.1332) rates were still not significantly different between patients treated with APBI-Brachy and WBI. CONCLUSION: Partial breast brachytherapy and WBI resulted in similar recurrence-free and overall survival rates in this cohort of elderly breast cancerpatients, even after adjustment for the more favorable characteristics of patients in the former group. These findings will need to be confirmed by the randomized trials comparing these modalities.
Authors: Jayant S Vaidya; David J Joseph; Jeffrey S Tobias; Max Bulsara; Frederik Wenz; Christobel Saunders; Michael Alvarado; Henrik L Flyger; Samuele Massarut; Wolfgang Eiermann; Mohammed Keshtgar; John Dewar; Uta Kraus-Tiefenbacher; Marc Sütterlin; Laura Esserman; Helle M R Holtveg; Mario Roncadin; Steffi Pigorsch; Marinos Metaxas; Mary Falzon; April Matthews; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2010-07-10 Impact factor: 79.321
Authors: Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Grace L Smith; Ying Xu; Thomas A Buchholz; Benjamin D Smith; Sharon H Giordano; Bruce G Haffty; Frank A Vicini; Julia R White; Douglas W Arthur; Jay R Harris; Ya-Chen T Shih Journal: J Clin Oncol Date: 2010-12-06 Impact factor: 44.544
Authors: Jack Hadley; K Robin Yabroff; Michael J Barrett; David F Penson; Christopher S Saigal; Arnold L Potosky Journal: J Natl Cancer Inst Date: 2010-10-13 Impact factor: 13.506
Authors: Kyna M Gooden; Daniel L Howard; William R Carpenter; April P Carson; Yhenneko J Taylor; Sharon Peacock; Paul A Godley Journal: Med Care Date: 2008-11 Impact factor: 2.983
Authors: Michael E Stokes; David Thompson; Eduardo L Montoya; Milton C Weinstein; Eric P Winer; Craig C Earle Journal: Value Health Date: 2008 Mar-Apr Impact factor: 5.725
Authors: Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin Journal: Cancer Date: 2008-06 Impact factor: 6.860
Authors: Igor Sirák; Miroslav Hodek; Pavel Jandík; Jakub Grepl; Petr Paluska; Jiří Petera Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241